Insights

GLP-1 Receptor Agonists and Cardiovascular Benefit
November 10, 2017 – 
Expert John Anderson, MD, reviews the cardiovascular outcomes data available to date with GLP-1 receptor agonists in type 2 diabetes.
Nondriver NSCLC: Immunotherapy and PD-L1 Expression
November 06, 2017 – 
Benjamin P. Levy, MD, explains the role of immunotherapy in patients with advanced nondriver non–small cell lung cancer and what is known about PD-L1 expression.
Immunotherapy and Chemotherapy in Second-Line NSCLC
November 06, 2017 – 
Benjamin P. Levy, MD, discusses patient and tumor responses to chemotherapy-based options and immunotherapy in the second-line setting and what treatments to use following an immunotherapy/chemotherapy combination in non–small cell lung cancer.
Understanding the Safety Data in CANVAS
November 03, 2017 – 
Expert John Anderson, MD, focuses on the adverse events in the CANVAS trial, providing important context for the data.
Practical Implications of the CANVAS Trial
November 03, 2017 – 
Expert John Anderson, MD, reviews data from the CANVAS trial with canagliflozin and offers his perspective on the practical implications of the recent findings.
NSCLC: Initiating Second-Line Therapy
October 30, 2017 – 
Benjamin P. Levy, MD, reviews the options for second-line therapy in non–small cell lung cancer including the goals of therapy, factors to consider when deciding on treatment, importance of aggressiveness of disease, and toxicity profiles.
Maintenance Following Chemotherapy in NSCLC
October 30, 2017 – 
Benjamin P. Levy, MD, describes his maintenance strategy following chemotherapy in patients with non–small cell lung cancer.
Diabetes: Shifting Mindset for Cardiovascular Benefits
October 25, 2017 – 
Expert John Anderson, MD, reviews data from the EMPA-REG OUTCOME trial with empagliflozin and discusses the impact the findings had on the diabetes field.
Complexities in Diabetes Care in 2017
October 25, 2017 – 
Expert John Anderson, MD, discusses the complexities involved in the management of diabetes and highlights the key factors to consider.
Nondriver NSCLC: Frontline Systemic Therapy
October 24, 2017 – 
Benjamin P. Levy, MD, explains the factors to consider when deciding on a treatment approach in the frontline setting of advanced nondriver non–small cell lung cancer and the use of immunotherapy/chemotherapy combinations.
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!